87 Results
Twenty-six years, one company, zero career plan to leave. Justin Westendorf of Phillips Medisize on the crushed rib that cost six months, the acquisition that changed inhalation, and why turning weaknesses into strengths is the wrong move.
He left 18 years at BCG to build a CDMO from zero inside a 70-year vaccine maker, betting on a 12-18 month sales cycle. Nine months later, HIPRA Biotech had its first client. Eduard Viladesau on the leap and what he never saw as an advisor.
Paperless labs, AI-ready teams, and 11 years at one company, Dr Rupesh Kelaskar on why staying long, thinking like an analyst, and understanding AI (not fearing it) defines the future of pharma QC.
CAR-T therapies can cure blood cancers. They cost $400k-$500k per patient. Ms. Archana Ganesh on why manufacturing — not science — is the last wall standing.
Dr Rajiv Desai on why India's next pharma milestone isn't cheaper generics, it's medicines the world calls Made in India.
A new parent leading baby care science at scale. Dr. Talluri on why clinical evidence — not marketing — is what consumers actually trust.
Dr Santosh Indraksha topped UPSC, left J&J's global postings, and joined CDSCO. On Schedule M, 295 medicines during COVID-19, QR codes, and why AI must assist regulators but never replace them.